Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection
Open Access
- 22 May 1997
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 336 (21), 1487-1493
- https://doi.org/10.1056/nejm199705223362103
Abstract
In patients with advanced human immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can become extensive and debilitating. Preliminary reports suggest that thalidomide may promote the healing of oral aphthous ulcers. We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients. The patients received a four-week course of either 200 mg of thalidomide or placebo orally once per day. They were evaluated weekly for the condition of the ulcers, their quality of life, and evidence of toxicity. Assays were performed for plasma tumor necrosis factor α (TNF-α), soluble TNF-α receptors, and HIV RNA. Sixteen of 29 patients in the thalidomide group (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only 2 of 28 patients in the placebo group (7 percent; odds ratio, 15; 95 percent confidence interval after adjustment for group sequential testing, 1.8 to 499; unadjusted P10 copies per milliliter; increase with placebo, 0.05; P = 0.04). With thalidomide treatment there were unexpected increases in the plasma concentrations of TNF-α and soluble TNF-α receptors. Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection.Keywords
This publication has 34 references indexed in Scilit:
- Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthaeBritish Journal of Dermatology, 2006
- Thalidomide Inhibits Tumor Necrosis Factor- Production by Lipopolysaccharide- and Lipoarabinomannan-Stimulated Human Microglial CellsThe Journal of Infectious Diseases, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- A Health Status Questionnaire Using 30 Items From The Medical Outcomes StudyMedical Care, 1991
- Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: Successful treatment with thalidomideJournal of the American Academy of Dermatology, 1990
- Significant response of oral aphthosis to thalidomide treatmentJournal of the American Academy of Dermatology, 1985
- THALIDOMIDE IN SEVERE OROGENITAL ULCERATIONThe Lancet, 1984
- Effect of thalidomide on orogenital ulceration.BMJ, 1983
- Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosisArchives of Dermatology, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958